All In Biotech

Drug Trial Radar · NCT06520826

Vafseo Outcomes In-Center Experience

Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,116

Actual

Start

Nov 20, 2024

Primary completion

Sep 10, 2026

Study completion Nov 5, 2026

Sponsor

Lead sponsor
USRC Kidney ResearchResearch network
Sponsor type
Research network
Collaborators
Akebia Therapeutics
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

  • VadadustatDrug

    A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.

  • Erythropoiesis Stimulating AgentDrug

    Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combination of the hierarchical endpoints of all-cause mortality and all-cause hospitalization.Time frame: 18 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • USRC Kidney Research

    Lone Tree, Colorado

  • Nephrology and Hypertension Specialists, PC

    Dalton, Georgia

  • US Renal Care - Gallup

    Gallup, New Mexico

  • Dallas Renal Group

    Dallas, Texas

  • US Renal Care - Live Oak

    Live Oak, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.